[5] She also began studying whether hormone drugs, such as tamoxifen, could allow patients with ductal carcinoma in situ to avoid surgery.
[6] In 2016, Hwang was chosen to lead the first United States based study on how to manage pre-cancers of the breast titled Comparison of Operative to Medical Endocrine Therapy.
The study focused on whether treatments for ductal carcinoma in situ were necessary or helpful in reducing the spread of the canercous tumours.
[7] Her focus on treatments for ductal carcinoma in situ reflect a conservative approach as she feels women are too often quick to choose mastectomies and suffer emotionally and physically afterwards.
[11] On May 3, 2019, Hwang was promoted to the Mary and Deryl Hart Distinguished Professorship of Surgery at the Duke Cancer Institute.